Acumen Pharmaceuticals, Inc. Common Stock
ABOSAcumen Pharmaceuticals, Inc. (ABOS) is a biotechnology company focused on developing therapies for neurodegenerative diseases, particularly Alzheimer’s disease. The company emphasizes innovative approaches to address the underlying causes of cognitive decline, aiming to improve patient outcomes through its research and development efforts in the neurodegeneration space.
Company News
Acumen Pharmaceuticals will report its Q3 2025 financial results on November 12, 2025, hosting a conference call and webcast to provide a business and financial update. The company is developing a novel therapeutic targeting toxic amyloid beta oligomers for Alzheimer's disease treatment.
Acumen Pharmaceuticals will participate in two upcoming investor conferences in September 2025, presenting its ongoing research into Alzheimer's disease treatment using sabirnetug (ACU193), a monoclonal antibody targeting toxic amyloid beta oligomers.
Acumen Pharmaceuticals will report Q2 2025 financial results on August 12, 2025, and host a conference call to provide a business and financial update, focusing on their Alzheimer's disease therapeutic candidate sabirnetug.
Acumen Pharmaceuticals will present research on cost savings and drug selectivity for sabirnetug, a potential Alzheimer's disease treatment, at the Alzheimer's Association International Conference in Toronto in July 2025.
Acumen Pharmaceuticals, a clinical-stage biopharmaceutical company, announced that it will report its first-quarter 2025 financial results on May 13, 2025.
